An overview of chemotherapy for mesothelioma

Hematology/Oncology Clinics of North America

Volumn 19, Issue 6, 2005, Pages 1117-1136

  Krug, Lee M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDATREXATE; ETOPOSIDE; FOLINATE CALCIUM; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMIDAZOLE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PEMETREXED; RALTITREXED; RANPIRNASE; RAZOXANE; SEMAXANIB; SORAFENIB; TEMOZOLOMIDE; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG; VATALANIB; VINBLASTINE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALIGNANT MESOTHELIOMA; META ANALYSIS; NEUTROPENIA; PERIOPERATIVE PERIOD; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MESOTHELIOMA; TREATMENT OUTCOME;

EID: 28444481384     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.09.010     Document Type: Review

References (106)

1. B. Price, and A. Ware Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003 Am J Epidemiol 159 2 2004 107 112
2. P.A. Janne Chemotherapy for malignant pleural mesothelioma Clin Lung Cancer 5 2 2003 98 106
3. S. Tomek, and C. Manegold Chemotherapy for malignant pleural mesothelioma: past results and recent developments Lung Cancer 45 Suppl 1 2004 S103 S119
4. H.J. Lerner, D.A. Schoenfeld, and A. Martin Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience Cancer 52 11 1983 1981 1985
5. P.G. Sorensen, F. Bach, and E. Bork Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma Cancer Treat Rep 69 12 1985 1431 1432
6. N.J. Vogelzang, R. Taub, and D. Shin Phase III randomized trial of onconase vs. doxorubicin in patients with unresectable malignant mesothelioma: analysis of survival [abstract 2274] Proc Am Soc Clin Oncol 19 2000 577a
7. M.P. Kosty, J.E. Herndon II, and N.J. Vogelzang High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study. Cancer and Leukemia Group B 9631 Lung Cancer 34 2 2001 289 295
8. J.P. Steele, C.A. O'Doherty, and J. Shamash Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma Ann Oncol 12 4 2001 497 499
9. Y. Oh, R. Perez-Soler, and F.V. Fossella Phase II study of intravenous doxil in malignant pleural mesothelioma Invest New Drugs 18 3 2000 243 245
10. P. Baas, J. van Meerbeeck, and H. Groen Caelyx in malignant mesothelioma: a phase II EORTC study Ann Oncol 11 6 2000 697 700
11. L.Y. Dirix, J. van Meerbeeck, and D. Schrijvers A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma Ann Oncol 5 7 1994 653 655
12. J. Carmichael, B.M. Cantwell, and A.L. Harris A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma Eur J Cancer Clin Oncol 25 5 1989 911 912
13. M.K. Samson, L.P. Wasser, and E.C. Borden Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study J Clin Oncol 5 1 1987 86 91
14. A. Ardizzoni, R. Rosso, and F. Salvati Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: an Italian Lung Cancer Task Force (FONICAP) phase II study Cancer 67 12 1991 2984 2987
15. M.C. Pennucci, A. Ardizzoni, and P. Pronzato Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force Cancer 79 10 1997 1897 1902
16. D.M. Shin, F.V. Fossella, and T. Umsawasdi Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma Cancer 76 11 1995 2230 2236
17. C. Pinto, A. Marino, and M. Guaraldi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM Regimen) in malignant pleural mesothelioma Am J Clin Oncol 24 1 2001 143 147
18. D.M. Mintzer, D. Kelsen, and D. Frimmer Phase II trial of high-dose cisplatin in patients with malignant mesothelioma Cancer Treat Rep 69 6 1985 711 712
19. B.L. Zidar, S. Green, and H.I. Pierce A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study Invest New Drugs 6 3 1988 223 226
20. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 14 2003 2636 2644
21. J. van Meerbeeck, R. Gaafar, and C. Manegold Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 28 2005 6881 6889
22. T. Berghmans, M. Paesmans, and Y. Lalami Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis Lung Cancer 38 2 2002 111 121
23. E.K. Mbidde, S.J. Harland, and A.H. Calvert Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma Cancer Chemother Pharmacol 18 3 1986 284 285
24. N.J. Vogelzang, M. Goutsou, and J.M. Corson Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B Cancer Chemother Pharmacol 27 3 1990 239 242
25. D. Raghavan, P. Gianoutsos, and J. Bishop Phase II trial of carboplatin in the management of malignant mesothelioma J Clin Oncol 8 1 1990 151 154
26. A.G. Favaretto, S.M. Aversa, and A. Paccagnella Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study Cancer 97 11 2003 2791 2797
27. K. Fizazi, H. Doubre, and T. Le Chevalier Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study J Clin Oncol 21 2 2003 349 354
28. A. Hughes, P. Calvert, and A. Azzabi Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J Clin Oncol 20 16 2002 3533 3544
29. W. Schutte, T. Blankenburg, and K. Lauerwald A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma Clin Lung Cancer 4 5 2003 294 297
30. D. Kelsen, R. Gralla, and E. Cheng Vindesine in the treatment of malignant mesothelioma: a phase II study Cancer Treat Rep 67 9 1983 821 822
31. J.D. Cowan, S. Green, and J. Lucas Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study Invest New Drugs 6 3 1988 247 248
32. C. Boutin, M. Irisson, and J.C. Guerin Phase II trial of vindesine in malignant pleural mesothelioma Cancer Treat Rep 71 2 1987 205 206
33. G. Martensson, and S. Sorenson A phase II study of vincristine in malignant mesothelioma: a negative report Cancer Chemother Pharmacol 24 2 1989 133 134
34. J.P. Steele, J. Shamash, and M.T. Evans Phase II study of vinorelbine in patients with malignant pleural mesothelioma J Clin Oncol 18 23 2000 3912 3917
35. D.A. Fennell, J.P. Steele, and J. Shamash Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma Lung Cancer 47 2 2005 277 281
36. J. van Meerbeeck, C. Debruyne, and N. van Zandwijk Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group Br J Cancer 74 6 1996 961 963
37. N.J. Vogelzang, J.E. Herndon II, and A. Miller High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234 Ann Oncol 10 5 1999 597 600
38. D.A. Vorobiof, B.L. Rapoport, and M.R. Chasen Malignant pleural mesothelioma: a phase II trial with docetaxel Ann Oncol 13 3 2002 412 415
39. C.P. Belani, S. Adak, and S. Aisner Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group Clin Lung Cancer 6 1 2004 43 47
40. A.W. Maksymiuk, R.F. Marschke Jr, and H.D. Tazelaar Phase II trial of topotecan for the treatment of mesothelioma Am J Clin Oncol 21 6 1998 610 613
41. H.L. Kindler, J.E. Herndon, and C. Zhang CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B Lung Cancer 48 3 2005 423 428
42. T. Nakano, A.P. Chahinian, and M. Shinjo Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile Cancer 85 11 1999 2375 2384
43. J.P. Steele, J. Shamash, and C.S. Barlow Phase II trial of irinotecan, cisplatin and mitomycin C (IPM) in malignant pleural mesothelioma [abstract 1227] Proc Am Soc Clin Oncol 21 2002 307a
44. H.L. Kindler, F. Millard, and J.E. Herndon II Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B Lung Cancer 31 2-3 2001 311 317
45. J.P. van Meerbeeck, P. Baas, and C. Debruyne A phase II study of gemcitabine in patients with malignant pleural mesothelioma Cancer 85 12 1999 2577 2582
46. J.A. Davidson, and B.W.S. Robinson Gemcitabine activity on murine and human malignant mesothelioma cell lines show additive activity in combination with cisplatin Aust N Z J Med 27 1997 213
47. M.J. Byrne, J.A. Davidson, and A.W. Musk Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study J Clin Oncol 17 1999 25 30
48. A.K. Nowak, M.J. Byrne, and R. Williamson A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma Br J Cancer 87 5 2002 491 496
49. J.M. van Haarst, P. Baas, and C. Manegold Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma Br J Cancer 86 3 2002 342 345
50. O.P. Solheim, G. Saeter, and A.M. Finnanger High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study Br J Cancer 65 1992 956 960
51. N.J. Vogelzang, L.B. Weissman, and J.E. Herndon II Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study J Clin Oncol 12 7 1994 1436 1442
52. H.L. Kindler, C.P. Belani, and J.E. Herndon Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma Cancer 86 1999 1985 1991
53. C. Shih, L.L. Habeck, and L.G. Mendelsohn Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA) Adv Enzyme Regul 38 1998 135 152
54. P. Baas, A. Ardizzoni, and F. Grossi The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992) Eur J Cancer 39 3 2003 353 357
55. G.V. Scagliotti, D.M. Shin, and H.L. Kindler Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma J Clin Oncol 21 8 2003 1556 1561
56. P.A. Janne, C. Obasaju, and G. Simon A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma [abstract 7053] J Clin Oncol 23 2004 626
57. E. Andreopoulou, P.J. Ross, and M.E. O'Brien The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma Ann Oncol 15 9 2004 1406 1412
58. P.J. Hollen, R.J. Gralla, and A.M. Liepa Adapting the lung cancer symptom scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation Cancer 101 3 2004 587 595
59. R.J. Gralla, P.J. Hollen, and A.M. Liepa Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument [abstract 2496] Proc Am Soc Clin Oncol 22 2003 621
60. J.E. Herndon, M.R. Green, and A.P. Chahinian Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 3 1998 723 731
61. M.J. Byrne, and A.K. Nowak Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 2 2004 257 260
62. M.F. Muers, R.M. Rudd, and M.E. O'Brien BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112 Thorax 59 2 2004 144 148
63. D.J. Girling, M.F. Muers, and W. Qian Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council Semin Oncol 29 1 2002 97 101
64. G. Giaccone, M.E. O'Brien, and M.J. Byrne Phase II trial of ZD0473 as second-line therapy in mesothelioma Eur J Cancer 38 Suppl 8 2002 S19 S24
65. S.M. Mikulski, J.J. Costanzi, and N.J. Vogelzang Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma J Clin Oncol 20 1 2002 274 281
66. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
67. V. Rusch, L. Saltz, and E. Venkatraman A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma J Clin Oncol 12 6 1994 1156 1163
68. M.Y. Chang, and D.J. Sugarbaker Innovative therapies: intraoperative intracavitary chemotherapy Thorac Surg Clin 14 4 2004 549 556
69. E. de Bree, S. van Ruth, and P. Baas Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma Chest 121 2 2002 480 487
70. H.I. Pass, B.K. Temeck, and K. Kranda Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma Ann Surg Oncol 4 8 1997 628 633
71. S. Yajnik, K.E. Rosenzweig, and B. Mychalczak Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma Int J Radiat Oncol Biol Phys 56 5 2003 1319 1326
72. D.J. Sugarbaker, R.M. Flores, and M.T. Jaklitsch Resection margins, extrapleural node status, and cell type determine post-operative long term survival in trimodality therapy of malignant pleural mesothelioma J Thorac Cardiovasc Surg 117 1 1999 54 63
73. W. Weder, P. Kestenholz, and C. Taverna Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma J Clin Oncol 22 17 2004 3451 3457
74. R. Flores, L. Krug, and K. Rosenzweig Induction chemotherapy, extrapleural pneumonectomy, and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma [abstract 7193] J Clin Oncol 23 2004 661
75. R.A. Stahel, W. Weder, and P. Ballabeni Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma: a multicenter phase II trial of the SAKK [abstract 7052] J Clin Oncol 22 2004 14S
76. L. Krug, H. Pass, and V. Rusch A multicenter phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma [abstract P-407] Lung Cancer 49 Suppl 2 2005 S223
77. M.A. Versnel, L. Claesson-Welsh, and A. Hammacher Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors Oncogene 6 11 1991 2005 2011
78. A. Mathy, P. Baas, and O. Dalesio Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial Lung Cancer 50 2005 83 86
79. M. Millward, F. Parnis, and M.J. Byrne Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma [abstract 912] Proc Am Soc Clin Oncol 22 2003 228
80. J.L. Villano, A.N. Husain, and W.M. Stadler A phase II trial of imatinib mesylate in patients with malignant mesothelioma [abstract 7200] J Clin Oncol 23 2004 663
81. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 16 2003 2149 2158
82. H. Dazzi, P.S. Hasleton, and N. Thatcher Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R): relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody Br J Cancer 61 6 1990 924 926
83. R. Govindan, J. Ritter, and R. Suppiah EGFR and HER-2 overexpression in malignant mesothelioma [abstract 3106] Proc Am Soc Clin Oncol 20 2001 339b
84. P.A. Janne, M.L. Taffaro, and R. Salgia Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma Cancer Res 62 18 2002 5242 5247
85. R. Govindan, R.A. Kratzke, and J.E. Herndon Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clin Cancer Res 11 6 2005 2300 2304
86. L. Garland, C. Rankin, and K. Scott Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 in patients with malignant pleural mesothelioma [abstract 3007] J Clin Oncol 22 2004 14S
87. M.C. Heinrich, C.L. Corless, and G.D. Demetri Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 23 2003 4342 4349
88. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
89. L. Strizzi, A. Catalano, and G. Vianale Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma J Pathol 193 4 2001 468 475
90. J. Konig, E. Tolnay, and T. Wiethege Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma Respiration (Herrlisheim) 67 1 2000 36 40
91. C. Linder, S. Linder, and E. Munck-Wikland Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma Anticancer Res 18 3B 1998 2063 2068
92. H.L. Kindler, N.J. Vogelzang, and K. Chien SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study [abstract 1359] Proc Am Soc Clin Oncol 20 2001 341a
93. H.L. Kindler, T. Karrison, and C. Lu A multi-center, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma [abstract] Proc Am Soc Clin Oncol 23 16S 2005 625s
94. T. Jahan, L. Gu, and X. Wang Vatalanib in patients with previously untreated advanced malignant mesothelioma: preliminary analysis of a phase II study by the cancer and Leukemia Group B (CALGB 30107) [abstract P-403] Lung Cancer 49 Suppl 2 2005 S222
95. P. Marks, R.A. Rifkind, and V.M. Richon Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 3 2001 194 202
96. W.K. Kelly, V.M. Richon, and O. O'Connor Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 10 Pt 1 2003 3578 3588
97. W.K. Kelly, O.A. O'Connor, and L.M. Krug Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 17 2005 3923 3931
98. Krug L.M., Kelly W.K., Curley T., et al. Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with malignant pleural mesothelioma. Presented at the 7th Meeting of the International Mesothelioma Interest Group (IMIG). Brescia (Italy), June 24-26, 2004
99. K.M. Skubitz Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma Cancer Invest 20 5-6 2002 693 699
100. B.L. Zidar, B. Metch, and S.P. Balcerzak A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study Cancer 70 10 1992 2547 2551
101. A.S. Alberts, G. Falkson, and L. Van Zyl Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna J Natl Cancer Inst 80 9 1988 698 700
102. G. Falkson, M. Hunt, and E.C. Borden An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma Invest New Drugs 10 4 1992 337 343
103. D. Bajorin, D. Kelsen, and D.M. Mintzer Phase II trial of mitomycin in malignant mesothelioma Cancer Treat Rep 71 9 1987 857 858
104. J.P. van Meerbeeck, P. Baas, and C. Debruyne A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma Eur J Cancer 38 6 2002 779 783
105. T. Sahmoud, P.E. Postmus, and C. van Pottelsberghe Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group Eur J Cancer 33 13 1997 2211 2215
106. G.A. Otterson, J.E. Herndon II, and D. Watson Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807) Lung Cancer 44 2 2004 251 259